The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hormone Refractory Prostate Cancer Market Research Report 2025
Synopsis
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hormone Refractory Prostate Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hormone Refractory Prostate Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hormone Refractory Prostate Cancer in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hormone Refractory Prostate Cancer include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer.
Report Scope
The Hormone Refractory Prostate Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Prostate Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Prostate Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Hormone Refractory Prostate Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Hormone Refractory Prostate Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Hormone Refractory Prostate Cancer in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Hormone Refractory Prostate Cancer include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer.
Report Scope
The Hormone Refractory Prostate Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hormone Refractory Prostate Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hormone Refractory Prostate Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Hormonal Therapy
1.2.4 Immunotherapy
1.2.5 Radiation Therapy
1.3 Market by Application
1.3.1 Global Hormone Refractory Prostate Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer Market Perspective (2019-2030)
2.2 Hormone Refractory Prostate Cancer Growth Trends by Region
2.2.1 Global Hormone Refractory Prostate Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hormone Refractory Prostate Cancer Historic Market Size by Region (2019-2024)
2.2.3 Hormone Refractory Prostate Cancer Forecasted Market Size by Region (2025-2030)
2.3 Hormone Refractory Prostate Cancer Market Dynamics
2.3.1 Hormone Refractory Prostate Cancer Industry Trends
2.3.2 Hormone Refractory Prostate Cancer Market Drivers
2.3.3 Hormone Refractory Prostate Cancer Market Challenges
2.3.4 Hormone Refractory Prostate Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue
3.1.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue (2019-2024)
3.1.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
3.4 Global Hormone Refractory Prostate Cancer Market Concentration Ratio
3.4.1 Global Hormone Refractory Prostate Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer Revenue in 2023
3.5 Hormone Refractory Prostate Cancer Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
3.7 Date of Enter into Hormone Refractory Prostate Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Prostate Cancer Breakdown Data by Type
4.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2019-2024)
4.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2025-2030)
5 Hormone Refractory Prostate Cancer Breakdown Data by Application
5.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Application (2019-2024)
5.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size (2019-2030)
6.2 North America Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hormone Refractory Prostate Cancer Market Size by Country (2019-2024)
6.4 North America Hormone Refractory Prostate Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size (2019-2030)
7.2 Europe Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hormone Refractory Prostate Cancer Market Size by Country (2019-2024)
7.4 Europe Hormone Refractory Prostate Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer Market Size (2019-2030)
8.2 Asia-Pacific Hormone Refractory Prostate Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer Market Size (2019-2030)
9.2 Latin America Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hormone Refractory Prostate Cancer Market Size by Country (2019-2024)
9.4 Latin America Hormone Refractory Prostate Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer Market Size (2019-2030)
10.2 Middle East & Africa Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Inc
11.1.1 Astellas Inc Company Detail
11.1.2 Astellas Inc Business Overview
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2019-2024)
11.1.5 Astellas Inc Recent Development
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Detail
11.2.2 Sanofi S.A Business Overview
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2019-2024)
11.2.5 Sanofi S.A Recent Development
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Detail
11.3.2 Dendreon Corporation, Bayer AG Business Overview
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2019-2024)
11.3.5 Dendreon Corporation, Bayer AG Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
